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Abstract: This work describes a novel screening strategy that implements small-scale spray-drying in early 
development of binary amorphous solid dispersions (ASDs). The proposed methodology consists of a three-
stage decision protocol in which small batches (20–100 mg) of spray-dried solid dispersions (SDSDs) are 
evaluated in terms of drug–polymer miscibility, physical stability and dissolution performance in bio-
predictive conditions. The objectives are to select the adequate carrier and drug-loading (DL) for the 
manufacturing of robust SDSD; and the appropriate stabilizer dissolved in the liquid vehicle of SDSD 
suspensions, which constitutes the common dosage form used during non-clinical studies. This methodology 
was verified with CDP146, a poorly water soluble 
(<2 µg/mL) API combined with four enteric polymers and four stabilizers. CDP146/HPMCAS-LF 40:60 (w/w) 
and 10% (w/v) PVPVA were identified as the lead SDSD and the best performing stabilizer, respectively. Lead 
SDSD suspensions (1–50 mg/mL) were found to preserve complete amorphous state during 8 h and maintain 
supersaturation in simulated rat intestinal fluids during the absorption window. Therefore, the 
implementation of spray-drying as a small-scale screening approach allowed maximizing screening 
effectiveness with respect to very limited API amounts (735 mg) and time resources (9 days), while removing 
transfer steps between screening and manufacturing phases. 
Keywords: amorphous solid dispersions; screening; spray-dryer; downscaling; polymers; miscibility; 
dissolution; supersaturation; stability 
                                                                
1 . Introduction 
Non-clinical testing is a mandatory step of drug development that aims to evaluate the 
pharmacodynamics, pharmacokinetics and toxicity profiles of new chemical entities (NCEs) so that safe initial 
dose level can be identified for the first human exposure [1]. In general, liquid suspension formulations 
represent the most common dosage form used during non-clinical studies because of their ease of preparation 
and applicability to the vast majority of non-clinical species [2,3]. Suspension formulations consist of the 
dispersion of drug solid particles throughout an aqueous medium containing additional excipients, typically 
emulsifying, suspending or ionizing agents as well as surfactants and solvents [4]. This standard non-clinical 
formulation is generally administrated to animals via oral gavage. Therefore, oral non-clinical formulations 
such as liquid suspensions differ 
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from conventional oral dosage forms used during clinical trials since tablets or capsules are not adapted for 
the dosing of most non-clinical species [5]. 
However, as the number of NCEs with poorly water soluble properties is continuously increasing during 
drug discovery phase, the conduction of non-clinical studies becomes challenging [3,6]. In this regard, the use 
of amorphous solid dispersions (ASD) has become a common strategy to tackle low solubility and improve 
absorption of the active pharmaceutical ingredient (API) in early drug development and formulation [7]. One 
of the major benefits of using ASD dosed as suspension formulation in comparison to the crystalline drug is 
the capability of producing adequate exposure of the API during non-clinical studies [8]. The strategy of solid 
dispersions consists of the drug amorphization and its dispersion into a polymeric carrier [9]. Spray-drying is 
considered as the solvent based process of reference for the manufacturing of solid dispersions in the 
pharmaceutical industry [10]. The key expectations regarding the development of a solid dispersion are the 
successful manufacturing of the amorphous form of the drug, its stability during the shelf life of the product 
and its capacity to maintain supersaturation during dissolution test [11]. 
Because, the selection of the appropriate polymer and drug-loading (DL) prior to the manufacturing of 
spray-dried solid dispersions (SDSDs) should be addressed in the first stage of the product’s development, the 
use of miniaturized screening methodologies have gained a large interest in the pharmaceutical industry. More 
specifically, solvent casting screening has been particularly used in the industrial sector due to its capacity to 
operate in an automated mode allowing the testing of a maximum number of carriers while using a minimum 
amount of drug product [12,13]. 
However, the effect of the preparation method on the properties of screened ASDs and, more generally, 
on the outcome of the screening is often underestimated [14]. The fact that standard screening methodologies 
e.g., solvent casting and quench cooling are not representative of the operating mode and process conditions 
of regular spray-dryer, increases the risk to generate ‘false negative and positive’ results [15,16]. These 
samples are known to display different properties in terms of drug–polymer miscibility, glass transition 
temperature (Tg), physical stability, inter-components interactions and dissolution kinetics between screening 
and manufacturing scale [15,17–19]. This limits the prediction accuracy of conventional screening approaches 
because API-polymer systems can be abandoned prematurely during screening phases or can present limited 
potential when manufactured. The frequency of conventional screening methods to generate ‘false 
negatives/positives’ is not evaluated in a systematic way and increases the risk of inappropriate carrier 
selection. Finally, transfer from screening phases to laboratory scale production generally requires time and 
resources as a set of new experiments need to be carried out in order to finetune optimal DL and determine 
appropriate processing conditions [8]. 
Considering the increasing number of poorly soluble NCEs requiring formulation to ASDs, and the 
drawbacks of the current screening processes, there is a need for the development of a more reliable screening 
method that would also be time-efficient and simple enough to be used on a routine basis by the industry. In 
this regard, this work aims to propose a novel screening strategy at preclinical scale that integrates laboratory 
spray-drying throughout all phases of API development from the screening phases to the first SDSD batch 
production to support GLP non-clinical studies. The novelty of this work is to overcome preconceived ideas 
about the use of laboratory spray-drying at small-scale and demonstrates its suitability to operate in the case 
of resource limited compounds as a practical solution for pharmaceutical scientists 
The present paper describes a new step-wise strategy for the (i) the screening of binary SDSD in early 
drug and formulation, and (ii) the development of SDSD dosed as non-clinical suspension formulation for oral 
administration. This novel screening approach was applied for CDP146: a poorly water soluble API from the 
UCB pipeline that is a candidate for the treatment of epilepsy. Firstly, the screening of appropriate polymer 
and optimal DL for the manufacturing of the lead SDSD that combines the best performance in terms of 
physical stability and solubility improvement was conducted during the first two stages of the proposed 
protocol. To do that the performance of API-polymer combinations made of four polymeric carriers (HPMCP 
HP50, HPMCAS-LF, Eudragit L100 and Eudragit L100-55) was examined. In the present study, the selection of 
enteric polymers is explained by their particular interest during non-clinical studies due to their ability to 
protect drug from recrystallization in gastric fluid and delay supersaturation until the drug reaches the upper 
small intestine so that absorption is maximized [20,21]. Furthermore, typical DL used during non-clinical 
studies is usually in the range 25–40% (w/w) [8,18]. Thus, a DL of 40% (w/w) was initially tested as it would 
allow reaching high doses (of up to 1 g/kg of drug administrated per day) in toxicology dose escalation studies 
while limiting the amount of excipients administrated to the animals with regard to toxicity and tolerability. 
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From experience, DL higher than 40% (w/w) can negatively impact the dissolution performance of ASDs by 
acting as a driving force for recrystallization. Secondly, the previously identified lead SDSD was prepared as 
liquid oral suspension formulation. The term ‘oral formulation’ refers to the preparation of SDSD suspended 
in the vehicle made of an aqueous medium containing HPC-SSL as standard suspending agent and one 
additional stabilizer. Although, the role of the carrier in ASD blend is to prevent drug from recrystallization in 
the solid state and during dissolution, the high doses usually tested during non-clinical studies generally 
require the use of an additional stabilizer dissolved in the liquid vehicle to ensure no physical change of the 
drug in the suspension that can negatively impact exposure. Accordingly, four conventional crystallization 
inhibitor agents including SDS, HPMC, Vitamin ETPGS and PVPVA have been screened. The choice of the above 
stabilizers and their concentration in the oral formulation vehicle have been carefully selected to minimize 
potential adverse effects and toxicity to the tested animals [4]. 
2. Material and Methods 
2.1. Materials 
Crystalline CDP146 was obtained from UCB Pharma, Product Development department 
(Braine l’Alleud, Belgium). The chemical structure of CDP146 is depicted in Figure 1. This compound has a 
molecular weight of 375.45 g/mol, a Tg of 95 ◦C, a melting temperature (Tm) of 198.1 ◦C. The API solubility in 
water was determined at 37 ◦C after 24 h under stirring (250 rpm) with drug content in excess within the 
aqueous medium. Following this procedure, the drug solubility was found to be below 2 µg/mL from pH 1.2 to 
pH 10.0. 
  
Figure 1. Chemical structure of CDP146. 
Four enteric polymers were evaluated as potential carriers for ASD: hydroxypropylmethylcellulose 
phthalate (HPMCP HP50) and hydroxypropylmethylcellulose acetate succinate fine grade (HPMCAS-LF) 
obtained from Shin-Etsu (Tokyo, Japan), copolymer of methacrylic acid and methyl methacrylate 1:1 (Eudragit 
L100) and copolymer of methacrylic acid and ethyl acrylate copolymer 1:1 (Eudragit L100-55) purchased from 
Evonik (Essen, Germany). Table 1 summarizes the physico-chemical and thermal properties of the selected 
carriers. 
Table 1. Physico-chemical properties of screened polymers for CDP146 ASD development. 
Polymer Mw (g/mol) a Dissolution pH a Tg (◦C) b T Degradation (◦C) c 
HPMCP-HP50 78,000 >5.0 140 160 
HPMCAS-LF 18,167 >5.5 122 170 
Eudragit L100 125,000 >6.0 192 165 
Eudragit L100-55 320,000 >5.5 122 165 
a data obtained from available literature [22]; b data experimentally obtained by modulated differential scanning calorimetry 
(mDSC); c data experimentally obtained by thermogravimetric analysis (TGA). 
Four stabilizers were tested with regard to the stabilization of suspension formulation: copolymer of N-
vinyl-2-pyrrolidone and vinyl acetate (PVPVA) from Ashland (Covington, KY, USA), sodium dodecyl sulfate 
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(SDS) from Merck (Darmstadt, Germany), hydroxypropylmethylcellulose (HPMC) and vitamin ETPGS from 
Sigma Aldrich (Saint-Louis, MO, USA). Hydroxypropylcellulose (HPC-SSL) from Nisso (Düsseldorf, Germany) 
was used for oral formulation preparation. Simulated intestinal fluids 
(SIF) powder was obtained from Biorelevant.com (London, UK) and used to simulate rat intestinal fluid. All 
other materials and solvents used were of reagent and analytical grade, respectively. 
2.2. Methods 
2.2.1. Screening Strategy 
General Considerations 
Figures 2 and 3 describe the experimental protocol summary and the flow chart representation of the 
proposed screening strategy, respectively. As seen in Figure 3, the proposed screening protocol uses a three-
stage decision tree including “Feasibility evaluation of SDSD manufacturing”, “Screening of polymer and 
stabilizer” and “Oral formulation development”. API and time consumption have been estimated while 
considering the screening of four polymers at two DLs (e.g., 30 and 40% (w/w)) for the manufacturing of 
binary SDSD, and four stabilizers dissolved in the liquid vehicle of the oral non-clinical formulation. • As a preliminary step of screening protocol, a common solvent or binary solvent mixture of interest that 
allows dissolving both drug and polymer, needs to be identified. A solute concentration higher than 2% 
(w/v) is defined as acceptance criteria for spray-drying development to achieve a reasonable yield, 
process time and solvent consumption to comply with HSE considerations [8,23]. • In the first Stage (S1), the potential of screened carriers was evaluated based on their ability to generate 
glass solutions by spray-drying. The evaluation of drug–polymer miscibility in the early stage of drug 
development is known to offer a reliable assessment of the ASD potential [24–26]. Specifically, the 
formation of glass solution system where amorphous drug is molecularly dispersed in the carrier, 
combines the best performance in terms of physical stability and solubility improvement [27]. On the 
contrary, semi-crystalline and phase-separated ASDs are known to provide limited potential of solubility 
enhancement and higher tendency for drug recrystallization during both dissolution and upon storage 
[28,29]. Commonly used excipients for the preparation of solid dispersions include cellulose, 
polyvinlylpyrrolidone, poloxamer, polyethylene glycol or polymethacrylate derivatives [30]. These 
polymers are recognized as “generally regarded as safe” (GRAS) excipients. Additional criteria such as Tg, 
hygroscopicity, solubility in organic solvents, viscosifying properties, pH of hydration in water and solid 
solution capacity need to be considered regarding the carrier selection for the manufacturing of solid 
dispersions by spray-drying [31]. • In the second Stage (S2), the physical stability of API-polymer systems identified as glass solutions was 
assessed up to one week. In parallel, the dissolution properties of these ASDs was examined with and 
without stabilizers dissolved in aqueous medium. Therefore, the influence of the stabilizer in the dosing 
vehicle of the oral formulation and its ability to maintain drug supersaturation and parachute effect 
during dissolution tests were investigated. The use of stabilizer in the dosing vehicle of suspensions allows 
converting the API into suitable dosage form for administration to non-clinical species. The wide variety 
of stabilizers commonly used during non-clinical studies allows overcoming the diversity of molecule 
specific exposure limitations so that the formulation maintains stability, homogeneity and dosability 
within the range of doses tested [5]. • In the last Stage (S3), the long-term stability of the lead SDSD identified during Stage 2 was investigated 
for up to 3 months. Moreover, the lead SDSD was prepared as non-clinical suspension formulation in the 
vehicle containing the stabilizer of interest. Then, the oral formulation was prepared at various doses 
generally tested during non-clinical studies. Its stability prior to administration and dissolution 
performance in bio-predictive conditions were assessed. 
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Figure 2. Summary of the experimental protocol applied in the proposed screening strategy. 
 
Figure 3. Flow chart representation of the three-stages’ decisional screening strategy. 
Application to CDP146 ASD Screening • Feasibility evaluation of SDSD manufacturing (Stage 1) 
Productions of 20 mg batches of 40:60 (w/w) CDP146 ASDs with HPMCP HP50, HPMCAS-LF, Eudragit L100 
and Eudragit L100-55 were performed using the laboratory scale ProCept 4M8-TriX spray-dryer (Zelzate, 
Belgium). This equipment was selected due to its capability to operate with feed solution volume as low as 0.5 
mL and up to 24 L/8 h [32,33]. API-polymer solutions were prepared in Dichloromethane (DCM)/Ethanol (EtOH) 
2:1 (v/v) at 50 mg/mL. The feed solution was pumped to the nozzle via a peristaltic pump Watson Marlow 530S 
(Falmouth, Cornwall, UK) and adjusted at 1 g/min. Atomization of the feed solution into fine droplets was 
achieved using a bifluid nozzle with a diameter of 1.2 mm and an atomizing air pressure of 1.50 bars. Solvent 
evaporation was performed by using a drying gas airflow of 0.30 m3/min at an inlet temperature of 60 ◦C. A 
lateral cooling airflow of 100 L/min was applied to transfer powder from the bottom of the drying chamber to 
the small cyclone (height/diameter of 210 mm/40 mm) where particle separation occurs. The present 
manufacturing conditions have been specifically optimized to maximize the yield of small-scale batches of solid 
dispersions. In addition, a customized 3D printed funnel has been particularly developed to allow powder 
collection into a standard aluminum pan (TA Instruments, Leatherhead, UK) used for modulated differential 
scanning calorimetry (mDSC) analysis. This powder collection system allows reducing material loss during 
powder handling and eases the transfer for subsequent analytical characterization. After processing, the 
collected powders were stored in a vacuum oven for 48 h before analysis. Duplicate SDSD productions were 
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conducted per API-polymer combination to assess reproducibility: one batch was analyzed by mDSC while the 
repeated sample was analyzed by X-ray powder diffraction (XRPD). • Screening of polymer and stabilizer (Stage 2) 
100 mg batches of 40:60 (w/w) CDP146 solid dispersions identified as ‘glass solutions’ during Stage 1 
were produced by spray-drying. The same process and formulation conditions used for the 20 mg batch 
productions were maintained. In this particular case, spray-dried material was collected in a 2 mL glass vial 
(Waters, Saint-Quentin-en-Yvelines, France) connected to the 3D printed system. SDSDs were analyzed by 
mDSC and XRPD, respectively, to confirm up-scaling robustness and comparability between Stage 1 and Stage 
2 with regard to miscibility and solid state. The physical stability of produced solid dispersions was assessed 
after one week upon storage under both stress and ambient storage conditions. About 10 mg of spray-dried 
powder were placed in an incubator at 40 ◦C/75% Relative humidity (RH), 25 ◦C/60% RH and 25 ◦C dry storage 
conditions. The aforementioned storage conditions were selected in line with the ICHQ1A(R2) guidelines. After 
one week, SDSDs were analyzed by mDSC, XRPD and polarized light microscopy (PLM) to detect the presence 
of potential drug crystals formed upon storage. 
An accurate weight of 2.5 mg of SDSD (equivalent to 1 mg of API) was dosed into 1 mL of dissolution 
medium consisting of 50 mM phosphate buffer at pH 6.5 with stabilizers. Five dissolution media with different 
stabilizer compositions were tested: Vehicle A (no stabilizers), Vehicle B (1% (w/v) HPMC), Vehicle C (0.2% 
(w/v) SDS), Vehicle D (1% (w/v) vitamin ETPGS) and Vehicle E (10% (w/v) PVPVA). The dissolution profile of 
pure crystalline CDP146 was obtained in each dissolution medium so that the solubility improvement (%) of 
screened SDSD can be evaluated. The aforementioned dissolution conditions represent non-sink conditions 
with respect to the crystalline drug so that the ability of screened ASD to generate and maintain 
supersaturation can be assessed during the duration of the test [34]. Dissolution tests were carried out 
manually in 10 mL glass tube (VWR, Heverlee, Belgium). Mixtures were maintained at 37 ◦C under magnetic 
stirring at 250 rpm using Thermo 
Mixer C unit (Eppendorf, Hamburg, Germany). Samples of 100 µL were collected after 5, 30, 60, 
120, 180, 240, 360 and 1440 min and transferred into 0.45 µm ultrafree filter units (Merck Millipore, 
Burlington, MA, USA). Samples were centrifugated at 8000 rpm during 2 min. The filtrate was pipetted, 
properly diluted in H2O/Acetonitrile (ACN) 1/1 (v/v) and analyzed in High performance liquid chromatography 
(HPLC). • Oral formulation development (Stage 3) 
1 g of lead ASD of CDP146 was produced by spray-drying using the laboratory scale ProCept 4M8-TriX 
spray-dryer (Zelzate, Belgium). Drug–polymer solutions were prepared in the binary solvent mixture of interest 
DCM/EtOH 2:1 (v/v) at 50 mg/mL. The feed solution flow rate was adjusted at 5 g/min. An atomizing air 
pressure of 0.65 bars was applied to a 1.2 mm bifluid nozzle to create a spray. The drying gas airflow was set 
at 0.35 m3/min and maintained at 65 ◦C. The lateral cooling air was kept constant at 100 L/min and dried 
particles were separated from the exhaust air within the medium cyclone (height/diameter of 242 mm/60 
mm). After processing, the spray-dried material was stored in a vacuum oven for 48 h before analysis to 
eliminate the last traces of residual solvent. 
The solid state and miscibility of spray-dried material was analyzed by XRPD, PLM and mDSC, 
respectively, to confirm the results obtained during previous screening steps. Residual solvent analysis was 
carried by Thermogravimetric analysis (TGA). The long term stability of the lead SDSD of CDP146 was 
investigated up to 3 months at 40 ◦C/75% RH, 40 ◦C dry storage conditions and 25 ◦C/60% RH. Solid state 
evolution and residual solvent content were determined after 2 weeks, 1, 2 and 3 months. 
This would help to gain insight into the shelf life of the formulated drug. 
In order to obtain ASD suspension, SDSD powder was dispensed in a 100 mM citrate buffer 
(pH 4) vehicle containing 1% (w/v) HPC-SSL, 0.1% (w/v) antifoam and the stabilizer agent of interest identified 
during the second step of the screening procedure. Oral liquid formulation was prepared at various API 
concentrations of 1, 10, 30 and 50 mg/mL. Powder was accurately weighed into 4 mL Nalgene polypropylene 
vial (Thermo Fischer Scientific, Waltham, MA, USA), and half of the required amount of vehicle was added. The 
mixture was manually mixed during one minute in order to wet all solid particles. Then, the rest of the vehicle 
was poured into the mixture and the formulation was magnetically stirred at 350 rpm for at least 30 min to 
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remove the presence of air bubbles in the mixture and homogenize the suspension. The formulation stability 
and homogeneity was determined by XRPD, PLM and Raman spectroscopy up to 8 h corresponding to a 
working day, under magnetic stirring at 350 rpm. 
Dissolution profiles of CDP146 suspension formulation were obtained at various doses in bio-predictive 
conditions representative for the rat species. First, 2 mL of freshly prepared oral formulation was pipetted into 
a 10 mL glass tube. 2.4 mL of a medium containing HCl and NaCl (6.19 g/L) at pH 3.2, used to simulate the 
gastric medium of rat was added to the mixture. The dissolution was carried out at 37 ◦C under magnetic 
stirring at 250 rpm using Thermo Mixer C unit (Eppendorf, Hamburg, Germany). Temperature and magnetic 
stirring were maintained constant during the entire dissolution tests. Samplings of 100 µL were taken after 1, 
5, 10, 15 and 30 min. After 30 min of dissolution in simulated rat gastric fluid, 1 mL of the mixture was 
transferred and diluted with 1 mL of 100 mM phosphate buffer at pH 5.0 containing SIF powder (35.6 mM). 
This vehicle was used to simulate the composition of the first compartment of rat intestinal fluid. This 
procedure was repeated twice with the second and third compartment of rat intestinal fluids that consist of 
100 mM phosphate buffer at pH 5.0 containing SIF powder (14 mM) and 100 mM phosphate buffer at pH 6.0 
containing SIF powder (4 mM), respectively. A dilution factor of 2 from the gastric to each intestinal fluid was 
applied to be representative for physiological conditions. Samplings of 100 µL were taken after 1, 5, 10, 15, 30, 
60, 90 and 120 min. All samples were filtered on 0.45 µm ultrafree filter units (Merck Millipore, Burlington, 
MA, USA) and centrifugated at 8000 rpm during 2 min. Appropriate dilution in H2O/ACN 1/1 (v/v) was 
performed and API content was determined in HPLC. 
2.2.2. Analytical or Characterization Methods 
Modulated Differential Scanning Calorimetry 
The phase behavior and thermal properties of SDSD were analyzed in mDSC using TA Instruments Q1000 
calorimeter (TA Instruments, Leatherhead, UK). The chamber was purged with a 50 mL/min flow rate of dry 
nitrogen. Indium and sapphire disks were used to calibrate the temperature/enthalpy and heat capacity, 
respectively. The powder was analyzed in non-hermetic standard aluminum pans (TA Instruments, 
Leatherhead, UK). Samples were heated from 0 ◦C to 210 ◦C at 2 ◦C/min with a modulation of ±1 ◦C and a 
period of 40 s. Data was processed using Universal Analysis 2000 software (TA Instruments, Leatherhead, UK): 
Tg was reported as the mid-point of inflection in the step change observed in the reverse heat flow signal while 
crystallization and melting events were recorded in non-reverse and total heat flows. 
Thermogravimetric Analysis 
TGA experiments were conducted in a TGA Q500 (TA Instruments, Leatherhead, UK) in order to 
estimate the percentage of residual solvent and moisture content in spray-dried material. The chamber was 
swept by a 50 mL/min flow rate of dry nitrogen. Samples were set isothermally 5 min at 25 ◦C and heated to 
300 ◦C at 10 ◦C/min. Data were processed using the TA instruments software Universal Analysis 2000 
software (TA Instruments, Leatherhead, UK). 
X-ray Powder Diffraction 
The solid state of screened solid dispersions was characterized in XRPD. Analyses were performed on X 
Bruker AXS D8 Advance (Bruker, Karlsruhe, Germany). Monocrystal silicium holders were used during sample 
preparation. Analyses on powder were carried out over the range 3.5–30◦  at a scan speed of 2.5 s/step and a 
step size of 0.02◦ . Data was processed using Eva DIFFRAC-SUITE software (Bruker, Karlsruhe, Germany). 
XRPD analyses were also conducted in order to monitor the crystallization behavior of the oral liquid 
formulation. Samplings of 200 µL were taken after 0, 4 and 8 h and were subsequently centrifuged at 8000 
rpm during 2 min on 0.45 µm ultrafree centrifugal filter units (Merck Millipore, Burlington, MA, USA). The wet 
solid filtrate was collected from the filter and analyzed in XRPD over the range 3.5–30◦  at a scan speed of 0.1 
s/step and a step size of 0.02◦ . Then, a second analysis was conducted on the ‘dried’ product to evaluate the 
potential appearance of crystals after water 
evaporation of the wet solid filtrate. 
Polarized Light Microscopy 
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The observations were performed using a AX10 Zeiss light microscope (Carl Zeiss, Oberkochen, Germany) 
under polarized light. The samples were observed in the optical resolution ×400. 
Pictures were collected using Axiocam MRC5 and images were processed using Axiovision 4.0 software 
(Carl Zeiss, Oberkochen, Germany). The presence of crystallites was determined by the observation of 
birefractive entities under polarized light. 
Raman Spectroscopy 
Raman spectroscopy was used to monitor the crystallization behavior of ASD suspension formulation. 
Analyses were conducted on Raman RXN2 Hybrid Analyzer (Kaiser Optical Systems, Ann Arbor, MI, USA) using 
a 785 nm laser wavelength in reflexion mode. Spectra were acquired by coupling the analyzer with fiber-optic 
MR probe with an 1/8” immersion optic. Internal calibration and determination of optimal exposure time were 
performed prior to analysis. Analyses of both crystalline API and CDP146 ASD suspension in the vehicle of 
interest were conducted. The immersion optic was inserted in 1 mL of formulation, previously pipetted into a 
2 mL HPLC glass vial with PTFE/silicone septa (Waters, Saint-Quentin-en-Yvelines, France). The mixture was 
magnetically stirred at 350 rpm and spectra were collected every 15 min during 8 h. Measurements were 
carried out in a black chamber to prevent interference from ambient. The Raman shift of 150–1890 cm−1 was 
examined. Two regions of Raman spectra where crystalline API and freshly prepared ASD suspension were 
found to display significant differences in peak characteristics, were particularly investigated. Data was 
obtained with iC Raman software (Kaiser Optical Systems, Ann Arbor, MI, USA) and processed by Matlab 
R2017b (Mathworks, Natick, MA, USA). 
HPLC 
Determination of CDP146 content during dissolution tests was performed using HPLC coupled with UV 
detection. Measurements were conducted on an X Bridge C18 column (Waters, Saint-Quentin-en-Yvelines, 
France) at 45 ◦C. The injection volume was fixed at 20 µL and the detection was carried out by UV at 305 nm. 
The analytical method used a gradient mobile phase composed of a mixture of acetate buffer (pH 4.5) and 
acetonitrile at a flow rate of 0.8 mL/min. Data were processed by Empower 3 chromatography data software 
(Waters, Saint-Quentin-en-Yvelines, France). Standard solutions of pure CDP146 were prepared in H2O/ACN 
1:1 (v/v) to cover a calibration linearity over the concentration range of 1–75 µg/mL. 
3. Results and Discussion 
3.1. Feasibility Evaluation of SDSD Manufacturing (Stage 1) 
Screened CDP146-polymer systems were produced by spray-drying (20 mg). Yields ranging from 16–28% 
were obtained so that sufficient material was collected for subsequent solid state characterization. Therefore, 
API-polymer combinations were evaluated based upon their ability to form glass solutions after processing at 
a DL of 40% (w/w). Figure 4 displays the results obtained in the reverse heat flow signal of mDSC and the XRPD 
patterns of 20 mg ASD batches of CDP146. Glass solutions were obtained for SDSDs of CDP146 made with 
HPMCP HP50, HPMCAS-LF, Eudragit L100 and Eudragit L100-55. As seen in Figure 4A, the thermograms of 
these API-polymer systems display a clear Tg, balanced between the Tg of pure components in the blend. No 
drug melting endotherm was detected in both heat flow and non-reverse signals (data not shown). 
Additionally, the presence of a large amorphous halo and the absence of Bragg peaks in XRPD pattern confirm 
the complete amorphization of the drug after processing (Figure 4B). Similar analytic data obtained for the 
first and the second batch demonstrated that the operating mode of small-scale spray-drying leads to 
reproducible results. During a ‘real’ screening, the second batch production can be removed i.e., one single 
batch of screened solid dispersion (20 mg) can be analyzed both in mDSC and XRPD to minimize API 
consumption. 
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Figure 4. Reverse heat flow signals (A) and X-ray powder diffraction (XRPD) patterns (B) of 40:60 
(w/w) CDP146 SDSDs (20 mg) made with HPMCP HP50 (a), HPMCAS-LF (b), Eudragit L100 (c) and Eudragit L100-55 
(d). 
All tested ASDs were identified as molecularly dispersed glass solutions and can therefore continue in the 
screening process. At this stage, there is no need to test these API-polymer systems at higher or lower DLs. 
However, if residual crystallinity is detected for SDSD produced at a DL of 40% (w/w), additional experiments 
at lower DL (e.g., 30% (w/w)) would be needed. 
In the current case study, preliminary evaluation of CDP146 SDSD miscibility and solid state was not found 
to discriminate polymers; this can be explained on the basis that CDP146 has a relatively low tendency for 
recrystallization. According to the classification of Baird et al. (2010) that aims to categorize the crystallization 
tendency of APIs from undercooled melts, CDP146 was found to belong to the class III group i.e., molecules 
that display complete amorphization and no recrystallization during a heating/cooling/heating cycle in DSC 
[35]. Furthermore, the application of the proposed screening strategy in different UCB pharma development 
projects has demonstrated that the first screening stage allowed realizing a pre-selection of adequate carriers 
for the SDSD manufacturing of API with higher tendency for recrystallization (data not shown). Preliminary 
information regarding the API tendency for recrystallization would allow assessing the suitability for ASD as a 
formulation principle. Nevertheless, a decision regarding the selection of adequate carrier and DL for the 
development of SDSD cannot be based on the sole criteria of drug–polymer miscibility evaluation. Conduction 
of dissolution tests is required to assess the “true” performance of ASD to enhance API solubility. Herein, 
polymer screening would be performed in the second stage of the proposed approach by evaluating the 
potential of CDP146-polymer glass solutions in terms of solubility enhancement and physical stability upon 
storage. 
As a preliminary step of screening protocol, DCM/EtOH 2:1 (v/v) was identified as the binary solvent 
mixture of interest for CDP146 SDSD manufacturing. The objective was to keep the same mixture of solvent 
during the entire duration of the screening protocol because a change in solvent system could impact the final 
properties of SDSD such as morphology, particle size and solid state [15,36]. 
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3.2. Screening of Polymer and Stabilizer (Stage 2) 
Small batches (100 mg) of CDP146 ASDs previously identified as glass solutions were produced by spray-
drying. The solid state and miscibility of screened SDSDs was evaluated and results are summarized in Table 2. 
API-polymer systems were identified as ideal glass solutions and displayed similar Tg value than the respective 
samples produced at smaller scale. This finding confirms the results obtained during the first stage of the 
screening strategy and therefore controls the validity of our approach. 
Elimination of the process variability factor linked to the choice of the preparation method was achieved 
by implementing the same manufacturing process (i.e., spray drying) at various scales. This presents the main 
advantage of our current strategy compared to standard screening methodologies because the generation of 
‘false negatives and positives’ results during the screening phases is minimized and thereby the risk of 
inappropriate carrier and DL selection is reduced. Analytical results of screened ASD batches produced at 20 
and 100 mg scale confirmed that the properties of the produced SDSD are scale-independent. 
Table 2. Characterization summary of 40:60 CDP146 ASDs produced by spray-drying (100 mg). 
ASD Composition Yield  Miscibility/Solid State 
Polymer DL (w/w) Yield (%) Tg (◦C) Tm (◦C) XRPD Pattern/PLM 
HPMCP HP50 40% 68.1 113.5  - A 
HPMCAS-LF 40% 70.9 102.5  - A 
Eudragit L100 40% 71.8 163.4  - A 
Eudragit L100-55 40% 71.7 120.9  - A 
A: amorphous sample characterized by the presence of a large halo in XRPD and the absence of birefringence under PLM 
observations. 
The physical stability of the four CDP146 SDSDs was investigated up to one week under stress and 
ambient storage conditions. XRPD patterns of 40:60 (w/w) SDSDs of CDP146 stored during one week at 40 
◦C/75% RH, 25 ◦C/60% RH and 25 ◦C dry storage conditions, respectively, are depicted in Figure 5. No evidence 
of drug recrystallization was reported for the four API-polymer systems upon storage. The absence of both 
Bragg peaks in XRPD patterns and birefractive crystallites under polarized light observations reveal that the 
four screened SDSDs were found to maintain their complete amorphous state. 
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Figure 5. XRPD patterns of 40:60 (w/w) CDP146 SDSDs (100 mg) made with HPMCP HP50 (a), HPMCAS-LF (b), 
Eudragit L100 (c) and Eudragit L100-55 (d) after 1 week under stress and standard storage conditions. 
The four screened polymers i.e., HPMCP HP50, HPMCAS-LF, Eudragit L100 and Eudragit L100-55 were 
found to have similar potential to inhibit drug crystallization at solid state. This observation correlates well 
with the relatively high Tg value obtained for 40:60 (w/w) CDP146 SDSDs, detailed in Table 3. Solid dispersion 
with high Tg generate anti-plasticization effect that reduces the molecular mobility and therefore contributes 
to the drug stabilization in the amorphous state [37]. At this stage, the assessment of carrier’s potential to 
maintain amorphous state upon storage did not allow discriminating the four carriers. The selection of lead 
excipient would be conducted based on the dissolution performance of CDP146-polymer systems. Although 
the duration of the physical stability program did not discriminate API-polymer systems, this study would 
ensure that solid dispersions will remain physically stable between the manufacturing and the administration 
phases, which corresponds to an average duration of one week. Results regarding the chemical stability of 
screened ASDs are not presented in the current case study but would be of interest during Stage 2 [38]. 
Dissolution performance of API-polymer systems was evaluated at 37 ◦C in dissolution medium at pH 6.5 
with and without stabilizers. At this stage, the generation of supersaturated solution with solubility 
improvement compared to crystalline drug during a minimum of 4 h is required to maximize in-vivo exposure. 
This length of time corresponds to the maximum duration of the administration phase during preclinical tests, 
typically. Dissolution profiles of screened 40:60 (w/w) CDP146 SDSDs in various media are depicted in Figure 
6. 
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As seen in Figure 6a, the four screened ASDs showed a poor solubility enhancement compared to 
crystalline API which is probably explained by a sudden drug recrystallization in the first seconds of the 
dissolution testing. This indicates that the presence of a polymer is insufficient and addition of a stabilizer is 
needed to stabilize the supersaturated solution. Similarly in the presence of 1% (w/v) HPMC (Figure 6b), the 
dissolution profiles of the four tested SDSDs did not allow generating supersaturation and improving drug 
solubility, significantly. This invalidates the selection of HPMC as anti-nucleation/stabilizing agent for SDSDs of 
CDP146. 
 
Figure 6. Dissolution profiles of 40:60 (w/w) CDP146 SDSDs (100 mg) and pure crystalline API in 
50 mM phosphate buffer (pH 6.5) without stabilizer (a) or with 1% (w/v) HPMC (b), 0.2% (w/v) SDS (c), 1% (w/v) 
Vitamin ETPGS (d) and 10% (w/v) PVPVA (e) at an API concentration of 1 mg/mL. 
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Table 3. Characterization summary and physical stability evaluation of lead CDP146 SDSD produced by spray-drying (1 g). 
Lead ASD Process Considerations  Miscibility/Solid State Residual Solvent  Physical Stability  
Polymer DL (w/w) Yield (%) Tg (◦C)  Tm (◦C) XRPDPattern/PLM Weight Loss (%) 
25 ◦C/60% RH 40 ◦C Dry 40 ◦C/75% RH 
1 m 2 m 3 m 1 m 2 m 3 m 1 m 2 m 3 m 
HPMCAS-LF 40% 88.2 102.5  - A 0.2 A A A A A A A A A 
A: amorphous sample characterized by the presence of a large halo in XRPD and the absence of birefringence under PLM observations. 
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When adding 0.2% (w/v) SDS or 1% (w/v) Vitamin ETPGS in the dissolution medium, the dissolution 
profiles of the four screened SDSDs of CDP146 were found to generate supersaturation in the first 
minutes/hours of the tests, as seen in Figure 6c,d. The best performing API-polymer combinations include 
HPMCAS-LF and Eudragit L100 carriers in dissolution medium containing 1% (w/v) Vitamin ETPGS and 0.2% 
(w/v) SDS, respectively. These specific ASDs were found to maintain supersaturation up to 3 h corresponding 
to a solubility improvement of around 720% and 561% after 3 h, respectively. However, recrystallization during 
dissolution testing characterized by sudden drop in solubility was recorded for all ASDs, as seen in Figure 6c,d. 
Consequently, the stabilizing potential of SDS and Vitamin ETPGS is not enough to cover the administration 
phase and alternative stabilizers need to be considered. 
Finally, dissolution profiles obtained for all 40:60 (w/w) CDP146 SDSDs in the medium containing 
10% (w/v) PVPVA allowed generating and maintaining supersaturation and parachute effect up to 24 h, 
corresponding to a solubility improvement percentage of around 1000% compared to the crystalline drug. 
Therefore, PVPVA was found as the best performing stabilizer that allowed sustaining supersaturation 
generated by 40:60 (w/w) CDP146 SDSDs during a length of time that covers the administration phase. 
Regarding the selection of adequate carrier, the four screened SDSDs of CDP146 display similar dissolution 
profiles in the dissolution medium made with 10% (w/v) PVPVA and could be selected, independently. 
Nevertheless, results obtained in the vehicle made with 1% (w/v) Vitamin ETPGS can be considered as 
discriminative conditions and confirm that CDP146/HPMCAS-LF 40:60 
(w/w) was the only API-polymer combination that reached drug solubility above 900 µg/mL up to 180 min, as 
seen in Figure 6d. All other ASDs recrystallize during dissolution test before 60 min and lost their solubility 
enhancement potential, consequently. HPMCAS-LF was found to have a greater potential than other tested 
carriers in terms of the degree of supersaturation generated and the extent of supersaturation maintenance. 
Based on these considerations, HPMCAS-LF was selected as adequate carrier for the manufacturing of 
CDP146 SDSD. 
Furthermore, in the case where the interplay between carrier and stabilizer does not allow maintaining 
supersaturation during a sufficient time to cover the administration phase, two alternatives can be considered: 
the potential of other stabilizers alone or in combination (e.g., Tween 80, PEG, Soluplus, PVPK15, Docusate, 
cellulose derivatives . . . ) can be evaluated and/or considering SDSD with lower DL (e.g., 30% (w/w)) at this 
stage of the screening approach. Decreasing the DL of solid 
dispersions is generally known to ease the stabilization of supersaturated solution [18]. 
3.3. Oral Formulation Development (Stage 3) 
A 1 g batch of CDP146/HPMCAS-LF 40:60 (w/w), previously identified as lead API-polymer system was 
produced by spray-drying. The solid dispersion was characterized in terms of solid state, miscibility and 
residual solvent content. Results are summarized in Table 3. This SDSD displays a single Tg of around 102 ◦C in 
the reverse heat flow of mDSC and the absence of melting and recrystallization process in the non-reverse and 
total heat flow signals. Large amorphous halo in XRPD pattern confirms the complete drug amorphization after 
processing. The results obtained in Table 3 correlate well with the properties of CDP146/HPMCAS-LF 40:60 
(w/w) generated during the first two stages of the screening approach. This confirms the advantage of the 
proposed screening strategy compared to standard screening methodologies because limited scale-up effects 
are observed with this approach and the same manufacturing technology is used during screening and 
manufacturing stages reducing the need for additional formulation/process development. 
Additionally, the physical stability of the lead SDSD of CDP146 was assessed up to three months at 40 
◦C/75% RH, 40 ◦C dry storage conditions and 25 ◦C/60% RH. Results from stability study are summarized in 
Table 3. Under both ambient and stress conditions, CDP146/HPMCAS-LF was found to maintain complete drug 
amorphous state during the entire duration of the stability program, which is a good indicator for the long-
term stability of the spray-dried material. This helps to gain insight into the shelf life of the product and allows 
covering drug development up to GLP toxicology studies [8]. 
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Evaluation of long-term stability using Atomic force microscopy (AFM) at this stage of the formulation 
development can help in the reduction of stability program from months to hours, by detecting phase 
separation in solid dispersions systems at nanometer scale [39]. 
In the scope of preclinical studies, lead SDSD of CDP146 was prepared as suspension in a liquid vehicle 
that contains the stabilizer agent of interest identified during Stage 2 (i.e., 10% (w/v) PVPVA) combined with 
1% (w/v) HPC-SSL as a standard suspending agent and 0.1% (w/v) antifoam in 100 mM citrate buffer (pH 4). 
The influence of the API dose on the stability of the oral liquid formulation was assessed at 1, 10, 30 and 50 
mg/mL during 8 h by monitoring drug crystallization in the formulation. The assessment of suspensions 
stability is a mandatory step before oral administration to animals in order to ensure that no physical change 
of the ASD has occurred as it can negatively impact drug exposure and lead to misleading interpretation of in-
vivo results. XRPD patterns of the wet solid filtrate collected from the oral formulation at t0, t4h and t8h, are 
depicted in Figure 7. Results obtained in XRPD reveal that the ASD in suspension remained amorphous in the 
vehicle and did not convert into its original crystalline state even after 8 h at an API concentration of 50 mg/mL. 
Similar results were obtained in XRPD after evaporation of the wet solid filtrate, while PLM observations 
confirm the 
lack of birefringence of the ASD suspension (data not shown). 
 
Figure 7. XRPD patterns of the wet solid filtrate collected from the suspension of CDP146/HPMCAS-LF 40:60 
(w/w) in 10% (w/v) PVPVA, 1% (w/v) HPC-SSL and 0.1% (w/v) antifoam in 100 mM citrate buffer (pH 4) at 1, 
10, 30 and 50 mg/mL. 
Figure 8 depicted the Raman spectra of crystalline CDP146 and ASD suspension of CDP146/HPMCAS-LF 
40:60 (w/w) prepared at 10 mg/mL and acquired after 0, 4 and 8 h under magnetic stirring (350 rpm). As seen 
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in Figure 8, arrows represented in the Raman spectrum of crystalline API point the characteristic peaks of 
crystalline CDP146 that displayed significant difference from its amorphous counterpart in a selected region 
of the Raman Shift. Moreover, the Raman spectra of ASD suspension obtained after 4 and 8 h in the 
formulation vehicle appear to be identical to the freshly prepared formulation. As no specific peak changes 
were observed during the run, it is likely that the ASD suspensions remained in the amorphous state 
throughout the studied time. This provides evidence of the formulation capacity to remain amorphous up to 
8 h and confirms the previous results obtained in XRPD and PLM. The aforementioned considerations 
regarding the stability of the oral formulation confirm the choices made with respect to carrier selection, DL 
and stabilizer used in the liquid vehicle. Although Raman spectroscopy was used to double-check the results 
obtained from XRPD and therefore confirms the formulation stability, its application might be optional in order 
to speed up the oral formulation development process. 
 
Figure 8. Raman spectra of pure crystalline CDP146 and CDP146/HPMCAS-LF 40:60 (w/w) suspensions (10 mg/mL) 
recorded at t0, t4h and t8h. 
Since the ASD suspension formulation was found to maintain its amorphous state for longer than the 
transit time of species used during preclinical studies, the potential of the oral formulation to enhance drug 
solubility in bio-predictive conditions was evaluated. In this regard, in-vitro dissolution that intended to mimic 
the gastro-intestinal tract of rat species was conducted as it constituted the most commonly used model 
during preclinical studies [8]. Dissolution profiles of crystalline drug and oral formulation prepared at various 
API concentrations in gastric medium and rat intestinal simulated compartments, are depicted in Figure 9. 
Solubility improvement percentages of oral formulation compared to crystalline drug in gastric and intestinal 
fluids after 30 and 60 min, respectively, are given in Figure 10. As seen in Figure 9, oral formulation prepared 
at four different API doses was found to enhance drug solubility, considerably in both gastric and intestinal 
fluids. Solubility improvement of about 1000% was obtained for oral formulation prepared at 10–50 mg/mL in 
intestinal compartments. The dissolution profile of each formulation displayed a plateau during the entire 
duration of the dissolution tests with no recrystallization process. The capacity of the tested oral formulation 
to maintain supersaturation in intestinal compartment of rat during the absorption window would allow 
enhancing oral drug bioavailability, considerably. The fact that drug did not recrystallize from supersaturated 
solution in gastric and first compartment of intestine can be partially attributed to the role of enteric carrier 
to delay drug release below the pH of polymer hydration. This confirms the great potential of using enteric 
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polymer in the scope of preclinical activities. Despite a dilution factor of 2 between the gastric medium to the 
intestinal fluid, the solid dispersion formulation was found to display a ‘reservoir’ effect by recovering high 
drug solubility in the first minutes of dissolution in each intestinal compartment. Moreover, the different 
concentrations of supersaturation generated in each of the intestinal compartments, can be attributed to the 
different compositions of bile salts. As an example, the level of drug concentration reached by the 50 mg/mL 
formulation was reduced by a factor 2 between the first two intestinal compartments when SIF content was 
decreased from 35.6 mM to 14 mM. Additionally, no major difference was obtained in the dissolution profile 
of formulation prepared at 10–50 mg/mL. This can be explained on the basis that at 10 mg/mL, the amorphous 
solubility is reached in each of the biofluids and increasing API dose to 50 mg/mL cannot exceed this value. 
Further results generated during in-vivo studies would be necessary to compare the potential of 10–50 mg/mL 
formulations. Additional tests including drug absorption simulation by a biphasic system can be examined to 
discriminate formulation prepared at various doses [13]. At this stage, the conduction of dissolution tests in 
bio-predictive conditions reveals that oral formulation in the API dose range of 1–50 mg/mL was found to fulfill 
the necessary requirements to be addressed during in-vivo administration studies. In this regard, larger batch 
production of CDP146/HPMCAS-LF 40:60 (w/w) can be performed to support the preclinical studies. 
Rat  
Gastric  
medium 
pH 3.2 
Rat Intestinal simulated fluid 
Compartment 1  Rat Intestinal simulated Compartment  2   Rat Intestinal simulated Compartment 3   
 
Figure 9. Dissolutions profiles of CDP146/HPMCAS-LF 40:60 (w/w) suspension and pure crystalline 
API in bio-predictive conditions mimicking gastro-intestinal tract of rat species at an API concentration of 1, 10, 
30 and 50 mg/mL. 
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Figure 10. Solubility improvement (%) of CDP146/HPMCAS-LF 40:60 (w/w) suspension compared to crystalline drug 
after 30 and 60 min in gastric and intestinal fluids, independently. 
This novel screening approach developed internally at UCB Pharma has been found to provide a rational 
selection of polymer and DL prior to the development and manufacturing of SDSD. The proposed three-stage 
decision protocol has been successfully applied in several projects and respects the development constraints 
in terms of API consumption and time resources. A maximum amount of 735 mg of API and a duration of 9 
days are required in order to screen four polymers and four stabilizers at two different DLs. In the current case 
study, 600 mg of CDP146 and 9 days were needed from solvent screening stage to the oral formulation 
optimization. 
Additionally, during the traditional ASD pathway development, once the lead API-polymer system has 
been identified, an additional step including process development using mini spray-dryer is required to 
finetune optimal DL and identify robust processing and formulation conditions for the manufacturing of SDSD. 
This transfer stage from screening to mini spray-dryer is basically based on a ‘trial and error’ approach and 
requires significant investment in time and API. In a recent study, Wyttenbach et al. (2013) estimated that the 
traditional ASD solvent casting program using rotary evaporator requires 16 weeks of development time and 
up to 10 g of API to screen 5 polymers at 2 DLs before the first ASD batch production can be started using mini 
spray-dryer [18]. In contrast to that, the implementation of spray-drying in a small-scale approach as it occurs 
for the first time in the proposed strategy allows removing this supplementary stage in ASD development. 
Herein, the downscaling approach proposed in the current study constituted a more simple and efficient 
methodology than traditional formulation development, reducing API consumption by a factor 13 and 
screening/formulation development time by a factor 12. 
Contrary to classical ASD development using film casting or quench cooling during the screening phase, 
the proposed strategy allowed reducing the influence of the preparation method on the polymer and DL 
selection. Based on experience, it is almost impossible to change the carrier identified during screening phases 
once the manufacturing phase has started. Results obtained in the current study highlighted that small-scale 
batches of SDSD generated in the first stage of the screening strategy display similar properties in terms of 
miscibility, Tg value and solid state compared to larger scale production. This allows to finetune DL selection in 
the first stage of screening stage and gain insight into the final performance of SDSD. 
Particular attention has been paid to propose a screening strategy where only standard analytical 
equipment were needed, to ensure this approach can be simple enough to be applicable in various 
pharmaceutical development laboratories. To enable solid state and miscibility characterization of screened 
SDSDs before and after incubation, the use of mDSC, XRPD and PLM was combined. 
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Non-sink dissolutions conditions with regard to the crystalline API were performed to assess the solubility 
enhancement potential of screened SDSDs and the extent of supersaturation. 
Although drug–polymer interactions have not been investigated, the authors assume that the results 
obtained during the physical stability studies and dissolution tests provide valuable information on the 
polymer’s potential to interact with the drug by preventing recrystallization [40]. Additionally, the systematic 
evaluation of drug–polymer miscibility has given insight into solid dispersion performance and homogeneity 
i.e., the formation of ideal glass solution is a proof of drug–polymer homogeneity at molecular level. Further 
studies will focus on adapting this screening approach for the development of ternary SDSDs in which a second 
polymer/surfactant is added to the ASD blend to improve the solid state stabilization of the amorphous drug 
as well as the maintenance of supersaturation during dissolution [41,42]. 
4. Conclusions 
The proposed screening approach implements for the first time spray-drying in a methodical small-scale 
approach for the development of ASD during preclinical activities. This novel screening strategy based on a 
three-stage decision protocol was verified with CDP146 by evaluating the performance of SDSDs in terms of 
drug–polymer miscibility, physical stability and in-vitro dissolution. Among the four polymers screened, 
HPMCAS-LF was found as the adequate carrier to provide physically stable SDSD of CDP146 at 40% (w/w) DL. 
Best performing stabilizer (10% (w/v) PVPVA) was identified during Stage 2 of the proposed strategy, to help 
maintain supersaturation during the absorption window of orally administrated suspension formulations. 
The total duration of the screening and the oral formulation development phases require 9 days and a 
maximum of 735 mg of API to screen four polymers and four stabilizers at two different DLs. In the current 
study where the screening protocol was verified with CDP146, only 600 mg of CDP146 and 9 days were needed. 
In this regard, the proposed screening approach can be classified as a material sparing approach, particularly 
adapted for the development of SDSDs in the industrial sector. Moreover, the choice of using only standard 
analytical equipment (e.g., mDSC, XRPD, PLM and TGA) during the screening protocol would ensure wide 
applicability and facilitate its use to a large number of development groups in the pharmaceutical industry. 
Small ASD batches as low as 20 mg were obtained by spray-drying and were representative from larger 
scale SDSD productions in terms of drug–polymer miscibility and solid state. To this extent, this downscaling 
approach has never been reported in literature, previously and would allow reducing efforts to correlate 
information from bench to batch manufacturing. Compared to standard screening methodologies e.g., solvent 
casting and quench cooling, the proposed screening strategy would improve the prediction accuracy with 
regards to SDSD properties and performance, resulting in a de-risking and rational selection of appropriate 
carrier and DL. This is explained on the basis that the process variability factor linked to the choice of the 
preparation method is minimized. Application of this novel and superior screening approach in UCB projects 
has replaced previous practices as it demonstrated a straight pathway from screening to manufacturing phases 
and eased the drug development progress, considerably. 
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Abbreviations 
ACN Acetonitrile 
AFM Atomic force microscopy 
API Active pharmaceutical ingredient 
ASD amorphous solid dispersions 
DCM Dichloromethane 
DL Drug-loading 
EtOH Ethanol 
HPLC High performance liquid chromatography mDSC Modulated 
differential scanning calorimetry 
NCE New chemical entity 
PLM Polarized light microscopy 
RH Relative humidity 
SDSD Spray-dried solid dispersion SIF
 Simulated intestinal fluids 
Tg Glass transition temperature 
TGA Thermogravimetric analysis 
Tm Melting temperature 
XRPD X-ray powder diffraction 
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